BiotechTube
Home/Pipeline/Advanced T reg Therapy

Advanced T reg Therapy

Autoimmune Diseases

Pre-clinicalActive

Key Facts

Indication
Autoimmune Diseases
Phase
Pre-clinical
Status
Active
Company
Slate Bio

About Slate Bio

Slate Bio is an early-stage biotech developing a novel class of T regulatory (T reg) cell therapies for autoimmune diseases. The company's platform centers on engineering cytokines to selectively enhance the function and persistence of T reg cells, aiming to provide durable, disease-modifying treatments. Operating from the biotech hub of Cambridge, MA, Slate Bio is positioned in a high-growth therapeutic area with significant unmet medical need. As a private, pre-clinical company, its near-term focus will be on advancing its lead program(s) toward Investigational New Drug (IND) application and securing further venture capital funding.

View full company profile

Therapeutic Areas

Autoimmune DiseasesInflammatory Diseases

Other Autoimmune Diseases Drugs

DrugCompanyPhase
Humira (Adalimumab) BiosimilarNeuCloneEarly Preclinical
HBM7020Harbour BioMedDiscovery
R2006Harbour BioMedDiscovery
R7027Harbour BioMedDiscovery
ImmCelz™ PlatformCreative Medical Technology HoldingsPreclinical
Not specified in provided content3SbioVarious
Gavocabtagene autoleucelastellasPhase 1/2
TYK-101TYK MedicinesPhase 1
HCB206HanchorBioPreclinical
miR-124 ActivatorFormation BioPhase 2
Autologous Cell Therapy CollaborationLupagenPreclinical
Autoimmune Diagnostics Leadership InitiativeVibrant America Clinical LaboratoryCommercial